MGS, a global provider of integrated manufacturing solutions for complex, high-precision plastic components for healthcare and pharma applications, has announced that it has acquired Denmark-based Technolution, a fast-growing consultancy and development company within pharma and medtech.
This partnership establishes a position in the industry’s value chain—providing a seamless, vertically integrated solution from initial design ideation to final product delivery.
The acquisition brings together Technolution’s proven expertise in R&D, regulatory compliance, quality, and project management with MGS’ expertise in tooling, moulding and automation for drug delivery devices, diagnostics and more. By combining forces, Technolution and MGS mitigate project risks for their clients, and create an approach that streamlines the supply chain and accelerates time-to-market.
“Extending our offerings into the early stages of product development takes us to the next level of medical contract manufacturing,” said MGS CEO Paul Manley. “And like Technolution, we achieve our goals with the most important factor, our employees, and nurture a culture of pioneering spirit, enthusiasm and a will to succeed.”
Commenting on the new partnership, Technolution founder and primary shareholder Allan Spork said, “We’re very excited by this opportunity for our company. MGS has already acquired Formteknik, a provider of valuable services from the DFM/ESI to the validated upscale turn-key solution, with whom we have been working closely for more than a decade. Bringing us all together makes our offering uniquely comprehensive.”
For Technolution CEO Thomas Bach Agerslev, the partnership opens new prospects for the company and its stakeholders. “Having multiple providers is inefficient and costly for pharma and medtech companies. That’s why they increasingly demand end-to-end solutions from a single supplier such as Technolution and MGS. For customers, this means a more integrated process, smoother collaboration through all phases, and as a result, faster time-to-market.”